Cyclacel Pharma (CYCC) Tops Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Financial Fact:
Research and development: 2.41M
Today's EPS Names:
CCEL, SLP, TMQ, More
Financial Fact:
Research and development: 2.41M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Cyclacel Pharma (NASDAQ: CYCC) reported Q3 EPS of ($0.22), $0.04 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $309 thousand versus the consensus estimate of $80 thousand.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman lowers Mattel rating to Sell on macro and execution risks; shares dip
- Bloom Energy rejects short-seller report on finances and supply chain
- PepsiCo (PEP) Misses Q2 EPS by 1c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
